OPKO Health Investor Presentation — June 2020

Document content

NASDAQ: OPKForward Looking Statements

2 June 2020 |This presentation contains “forward -looking statements,” asthatterm isdefined under thePrivate Securities Litigation Reform Actof1995 (PSLRA), which statements may beidentified by

words such as“expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “potential,” and other words ofsimilar meaning, including statements

regarding ourestimated revenues andfinancial projections, including expected Rayaldee andBioReference revenues, whether wewillachieve profitable growth atBioReference ,whether

prescriptions forRayaldee willcontinue toincrease, expected milestones androyalties from theoutlicense ofourproducts, ourability toachieve high levels ofgrowth, thepotential forour

products under development andwhether wecandevelop them forcertain indications, potential development opportunities forFactor VII-CTP, oxyntomodulin andtheSARM candidate, aswell

asourearly stage raredisease product candidates, theexpected timing oftheclinical studies andregulatory approval forourproducts under development, theoutcome ofourclinical trials and

validation studies andthatsuch outcomes willsupport marketing approval orcommercialization, theexpected market penetration andsize ofthemarket forourproducts, including without

limitation, Rayaldee®, hGH-CTP, Factor VII-CTP, Alpharen, oxyntomodulin ,theSARM candidate, andourearly stage raredisease product candidates, potential benefits ofourproducts under

development, including thatoxyntomodulin willprovide superior long-term therapy forobesity andType IIdiabetes patients, ourability tosuccessfully commercialize ourproduct candidates

such ashGH-CTP, Alpharen ,Factor VII-CTP, theSARM, oxyntomodulin ,andourrare disease product candidates, andwhether Rayaldee willtake significant market share instage 3and4

CKD patients withSHPT, whether Rayaldee willraise serum total 25-hydroxyvitamin D(25D)more effectively than anyover-the-counter (OTC) orprescription (Rx) products currently marketed

without theriskofhypercalcemia, ourability todevelop Rayaldee fornew indications including stage 5CKD, andthetimeline fordoing so,whether theclinical data forhGH-CTP willsupport

submission ofaBiologics License Application (BLA) andapproval forhGH-CTP inadults andpediatric patients, whether wewillberequired tomake anychanges toourdevelopment plans for

hGH-CTP andincrease ourexpenditures, expectations regarding patent coverage, theexpected timing forcommencing, enrolling, completing andannouncing results forourclinical trials, the

timing forrelease oftrialdata andseeking andobtaining FDA andEuropean regulatory approvals aswellasreimbursement coverage forourproducts, andwhether payors willreimburse us